ProteoGenix Launches New Human and Rabbit Antibody Libraries to Speed Up the Discovery of Better Therapeutic and Analytical Antibodies

Strasbourg, France (October 29, 2019) – For researchers looking to accelerate the development of new immunotechnologies, ProteoGenix has created 2 new naïve rabbit and human antibody phage display libraries.

Phage display screening on our high-quality libraries allows skyrocketing the generation of high-affinity antibodies for therapeutic and analytical applications using animal-free approaches in only 6 to 7 weeks.

Our human antibody library – LiAb-SFMAX™ (3x10¹⁰ clones) – was developed for the highest possible diversity and it comprises the repertoire of 364 healthy donors from 5 different ethnic groups (Caucasian, Arabic, Black-African, Latino, and Asian). The use of fully human repertoires is the best possible approach for the generation of therapeutic antibodies. Using phage display in combination with our LiAb-SFMAX™ is the guarantee to obtain promising clinical candidates without the need for lengthy and expensive humanization processes.

Our rabbit antibody library – LiAb-SFRab™ (1x10¹⁰ clones) – was also built for maximized diversity containing the complete repertoire of 40 healthy rabbits from 4 different breeds (New Zealand White, Himalayan, Japanese White, and Hare). These antibodies are superior to traditional mouse antibodies due to their higher diversity, affinity, sensitivity, specificity, and ability to recognize unusual and hard-to-reach epitopes. These properties make them ideal for analytical applications such as ELISA, Western Blot, Immunohistochemistry, Immunoprecipitation, among others.

Save time and choose one of our naïve libraries for the generation of your analytical and therapeutic antibodies. For more information on ProteoGenix’s LiAb-SFRab™ (rabbit) and LiAb-SFMAX™ (human) libraries for phage display, click here. For more information on ProteoGenix’s complete antibody production services, click here.

About ProteoGenix – ProteoGenix is a world leader in peptide, protein and antibody production for therapeutic and analytical applications. Our mission is to help our customers developing new immunotechnologies and biotherapies. We provide personalized and specialized support during antigen discovery, design, and production, as well as antibody production using in vivo hybridomas or in vitro phage display technologies. ProteoGenix provides services to customers from all around the globe. For more information, please visit: www.proteogenix.science.

Contact Information:

Ana Reis

Web Marketing Department

Mathieu Schaff

Monoclonal Antibody Services – Account Manager

+33 (0) 390 20 54 70

contact@proteogenix.fr